264272-63-1

Basic information

• Product Name: 3-BroMo-4-(Methoxycarbonyl)benzoic acid
• Synonyms: 3-BroMo-4-(Methoxycarbonyl)benzoic acid;4-(methoxycarbonyl)-3-bromobenzoic acid;2-Bromo-terephthalic acid 1-methyl ester
• CAS NO: 264272-63-1
• Molecular Formula: C₉H₇BrO₄
• Molecular Weight: 259.05348
• Mol File: 264272-63-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 374.2±32.0 °C(Predicted)
• Appearance: /
• Density: 1.660±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.38±0.10(Predicted)
• CAS DataBase Reference: 3-BroMo-4-(Methoxycarbonyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BroMo-4-(Methoxycarbonyl)benzoic acid(264272-63-1)
• EPA Substance Registry System: 3-BroMo-4-(Methoxycarbonyl)benzoic acid(264272-63-1)

Safety Data

• Hazardous Substances Data: 264272-63-1(Hazardous Substances Data)

Usage

Uses

3-Bromo-4-(methoxycarbonyl)benzoic Acid is a reactant used in the synthesis and biological evaluation of retinoid x receptor-selective agonists.

Upstream product

• 10312-55-7 3-aminoterephthalic acid 
• 60728-41-8 1-methyl-2-aminoterephthalate 
• 7697-27-0 2-bromo-4-methylbenzoic acid 
• 1403326-85-1 4-benzyl 1-methyl 2-bromobenzene-1,4-dioate 
• 1403326-82-8 4-((benzyloxy)carbonyl)-2-bromobenzoic acid 
• 1403326-79-3 benzyl-3-bromo-4-formylbenzoate 
• 91760-66-6 3-bromo-4-formyl-benzoic acid 
• 1403326-77-1 4-(dibromomethyl)-3-bromobenzoic acid 
• 87808-49-9 2-bromo-4-methyl-benzoic acid methyl ester 
• 586-35-6 2-bromo-1,4-benzenedicarboxylic acid 
• 18643-86-2 dimethyl 2-bromoterephthalate 

Downstream Products

• 1204305-02-1 methyl 2-bromo-4-(chloro-carbonyl)-benzoate 
• 1331832-73-5 C₂₄H₂₇BrO₂ 
• 1403326-73-7 2-bromo-4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl)benzoic acid 
• 1403326-89-5 methyl 2-bromo-4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl)benzoate 
• 1403326-69-1 methyl 2-bromo-4-(1-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)vinyl)benzoate 
• 1437052-49-7 methyl 2-bromo-4-carbamoylbenzoate 
• 98592-04-2 methyl 2-bromo-4-cyanobenzoate 
• 1437052-52-2 1-(3-bromo-4-(2-hydroxypropan-2-yl)phenyl)ethanone 
• 1437052-55-5 1-(3-bromo-4-(2-(ethoxymethoxy)propan-2-yl)phenyl)ethanone 
• 1437052-58-8 1-(4-(2-(ethoxymethoxy)propan-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanone 
• 1437049-95-0 N-(2-(1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)propan-2-yl)-2-methyl-4-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)benzamide 
• 18643-86-2 dimethyl 2-bromoterephthalate 
• 1437052-76-0 2,2'-(2-bromo-1,4-phenylene)dipropan-2-ol 
• 1437052-79-3 2-bromo-1,4-bis(2-(ethoxymethoxy)propan-2-yl)benzene 

Relevant articles and documents

Diaryl 2- amide-substituted thiophene imide ester compound as well as preparation method and application thereof (by machine translation)

The invention also discloses a 2 - synthesis method thereof, and an application of the compound as an antibacterial agent, in the phthisis-caused by the bacterium, in particular to the, mycobacterium-induced infectious disease (especially (Tuberculosis,TB), mycobacterium- induced mycobacterium, tuberculosis), and (I) the invention, specifically relates to a pharmaceutical composition containing the compound of the present invention or, a R pharmaceutical composition comprising the compound of the present invention. 1 , R2 , R3 , R4 , R5 As described Y in the present invention. as described in the specification, the present invention is directed, to the preparation of novel compounds, having an anti-mycobacterial activity as potential, new drug (s) for the treatment (TB) or preventative treatment of infectious diseases, consisting of M. tuberculosis, in particular phthisis- caused by tubercular mycobacteria, while being useful in overcoming the problems associated with drug resistance. (by machine translation)

Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof

The present invention relates to new pyrano[3,2-c]benzopyran-6(2H)-one derivatives that act as SGLT2 inhibitors, which makes them promising candidates for the treatment of diabetes and other diseases and conditions mediated by SGLT2. These new drugs also exhibit platelet aggregation inhibitory activity which makes them promising candidates in the treatment and/or prevention of prothrombotic conditions. The invention also relates to the use of such pyrano[3,2-c]benzopyran-6(2H)-one derivatives in the treatment or prevention of the diabetes and other disorders and conditions mediated by SGLT2, as a single active ingredient or in combination with another antidiabetic agent or a drug for the treatment of hypertension, chronic heart failure or atherosclerosis, and pharmaceutical compositions comprising said new pyrano[3,2-c]benzopyran-6(2H)-one derivatives.

Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists: Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)

The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoidX receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC50 values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.